Sigliptin is a highly selective dipeptidyl peptidase 4 (DPP‐4) inhibitor, and can promote the islet β cells to synthesize and release insulin significantly by increasing the level of active incretin in T2DM patients. This evidence concerns the gene INS and type 2 diabetes mellitus.